Dhaval Shah, MD
Hematology & Oncology · Newark, DENPI 1063743722
Payments from drug & device makers
Across 69 payments — averaging $147.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$7K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$185
- AbbVie$164
- AstraZeneca$145
- Incyte Corporation$84
- plus $674 from 24 others
What the payments were for
- Consulting fees$2,20022%
- Speaking & faculty fees$4,50044%
- Travel & lodging$1,89519%
- Food & beverage$1,42514%
- Education$1411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 6 | $6,583 |
| Novartis | 6 | $2,325 |
| E.r. Squibb & Sons, L.L.C. | 5 | $185 |
| AbbVie | 4 | $164 |
| AstraZeneca | 4 | $145 |
| Incyte Corporation | 4 | $84 |
| Pfizer | 4 | $63 |
| Gilead | 3 | $58 |
| Sanofi | 3 | $54 |
| Amgen | 3 | $46 |
| Genentech USA, Inc. | 2 | $46 |
| Merck | 2 | $43 |
| Puma Biotechnology, Inc. | 3 | $42 |
| Beigene USA, Inc. | 2 | $39 |
| GSK | 2 | $37 |
| Bristol Myers Squibb | 1 | $29 |
| Syndax Pharmaceuticals, Inc. | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Seagen Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Dova Pharmaceuticals | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Epizyme, Inc. | 1 | $13 |
| Secura Bio, Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$120
How this compares
$10,161 in reported general payments places this provider in the 85th percentile of 26 hematology & oncology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 26 | $663,605 |
| TibsovoIvosidenib | 12 | $404,852 |
| BrukinsaZanubrutinib | 25 | $376,398 |
| XtandiEnzalutamide | 27 | $356,708 |
| Abiraterone Acetate | 168 | $329,795 |
| VerzenioAbemaciclib | 18 | $273,404 |
| Lenalidomide | 20 | $267,326 |
| InlytaAxitinib | 14 | $250,624 |
| ImbruvicaIbrutinib | 13 | $211,988 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $173,043 |
| CalquenceAcalabrutinib Maleate | 11 | $169,184 |
| XermeloTelotristat Etiprate | 13 | $123,699 |
| Lanreotide Acetate | 11 | $90,980 |
| EliquisApixaban | 56 | $60,929 |
| XareltoRivaroxaban | 51 | $46,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $39 | $376,39825 claims |
| Astellas Pharma US IncXtandi | $13 | $356,70827 claims |
| PfizerInlyta, Eliquis | $63 | $311,55370 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $16 | $211,98813 claims |
| NovartisMekinist | $2,325 | $173,04311 claims |
| AstraZenecaCalquence | $145 | $169,18411 claims |
| Johnson & JohnsonXarelto | $17 | $46,37751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 26 hematology & oncology providers in Delaware.
Other hematology & oncology in Newark
- Jamal MislehNewark$6M
- Sujung ParkNewark$15K
- Nicole LaslettNewark$11K
- Jason PalopoliNewark$4K
- Jamil KhatriNewark$2K
- Evan LapinskyNewark$2K
- Andrew HimelsteinNewark$2K
- Kathiresan SuppiahNewark$2K
- Ramya VaradarajanNewark$901
- Palak ShahNewark$750
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.